– Complete remission (CR) rate of 50% and overall response rate (ORR) of 66.7% in 18 evaluable patients with CMML treated with IO-202 in combination with azacitidine – – CR rate of 83.3% and ORR of ...
(RTTNews) - Cardiff Oncology, Inc. (CRDF) has presented new clinical data from an investigator-sponsored Phase 1 dose escalation trial evaluating onvansertib, a novel oral PLK1 inhibitor, in patients ...
"We found that being treated at an academic center was associated with improved survival, suggesting that specialized care for CMML is an important aspect of treatment." — Douglas Tremblay, MD, Tisch ...
(RTTNews) - Salarius Pharmaceuticals, Inc. (SLRX), a clinical-stage biopharmaceutical company, on Monday announced the resumption of patient enrollment in the investigator-initiated Phase 1/2 clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results